iVeena is a clinical stage ophthalmology company developing a non-surgical, non-invasive, pharmacologic innovation. This novel disease modifying intervention addresses a significant unmet need in the advancement of corneal diseases and myopic conditions. The company’s lead programs comprise of novel proprietary products; IVMED-80 for keratoconus and IVMED-85 for myopia.